Flavonoid and botanical approaches to prostate health

Journal of Alternative and Complementary Medicine

Volumn 8, Issue 6, 2002, Pages 813-821

  Katz, Aaron E ^a,b  

^a Columbia Univ School of Medicine ^*  (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC SOY ISOFLAVONES; BIOCHANIN A; CARLSON EASY SOY; CARLSON EASY SOY GOLD; CIMETIDINE; CURBICIN; DAIDZEIN; EQUOL; ERDIC; ESTROVEN; FINASTERIDE; FLAVONOID; FORMONONETIN; GENISTEIN; H AND B SOYA ISOFLAVONES; HERBACEOUS AGENT; ISOFLAVONE; KUDZU; N RESOURCES SOY ISOFLAVONES; NATURALLY PREFERRED SOY GERM; NEOARSPHENAMINE; NEW PHASE SUNSOURCE; NOVASOY; NUTRI SOY; PHYTOESTRIN; PHYTOSOY; PHYTOSOYA; PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; RED CLOVER EXTRACT; SABAL EXTRACT; SOLGAR; SOY CARE; SOY CHOICE VITANICA; SOY LIFE 25; SOYAMAX; SOYPLUS; SPRING VALLEY; SUNDOWN; TAMSULOSIN; TERAZOSIN; TRINOVIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CLOVER; DIET THERAPY; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EJACULATION DISORDER; FATIGUE; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE; MEDICINAL PLANT; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PYGEUM; RED CLOVER; RHINITIS; SABAL; SOYBEAN; SQUASH; TRANSURETHRAL RESECTION; VERTIGO;

EID: 0036976696     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/10755530260511829     Document Type: Article

References (40)

1. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342:1209-1210.
2. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5595.
3. Altwein JE. Obstructive benign prostatic hyperplasia: therapeutical aspects. Eur Urol 1998;34(Suppl 1):31-37.
4. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990;17:495-507.
5. Barry MJ, Mulley AG Jr, Fowler FJ, Wennberg JW. Watchful waiting vs. immediate transurethral resection for symptomatic prostatism: The importance of patients' preferences. JAMA 1988;259:3010-3017.
6. Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Blane G, Chadha-Boreham H. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): A multicentre trial in central Europe. Curr Med Res Opin 1998;14:127-139.
7. Campbell DR, Kurzer MS. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Mol Biol 1993;46:381-388.
8. Carani C, Salvioli V, Scuteri A, Borelli A, Baldini A, Granata AR, Marrama P. [Urological and sexual evaluation of treatment of benign prostatic disease using Pygeum africanum at high doses]. Arch Ital Urol Nefrol Androl 1991;63:341-345.
9. Carbin B-E, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 1990;66:639-641.
10. Collins BM, McLachlan JA, Arnold SF. The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids 1997;62:365-372.
11. Délos S, Carsol J-L, Ghazarossian E, Raynaud J-P, Martin P-M. Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol 1995;55:375-383.
12. Department of Veterans Affairs Cooperative Study of Transurethral Resection for Benign Prostatic Hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993;150:1696-700.
13. Di Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera M, Sciarra F. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-314.
14. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-252.
15. Evans BAJ, Griffiths K, Morton MS. Inhibition of 5α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995;147:295-302.
16. Flomax® (tamsulosin hydrochloride) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, 1999.
17. Gaynor ML, Hickey J. Soy and genistein. In: Dr. Gaynor's Cancer Prevention Program. New York, NY: Kensington Publishing, 1999:89-100.
18. Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: Effects on urodynamic parameters and voiding symptoms. Urology 1998;51:1003-1007.
19. 1-adrenoceptors in vitro. Prostate 1999;38:208-215.
20. Graversen PH, Gasser TC, Wasson JH, Hinman F Jr, Bruskewitz RC. Controversies about indications for transurethral resection of the prostate. J Urol 1989;141:475-481.
21. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study. J Natl Cancer Inst 1998;90:1637-1647.
22. Howes JB, Eden J, Waring M, Huang L, Howes LG. Acute and chronic pharmacokinetics of an extract of isoflavones from red clover. Climacteric (in press).
23. Hytrin® (terazosin hydrochloride) [package insert]. North Chicago, IL: Abbott Laboratories, 1996.
24. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998;9:553-557.
25. Janson M. Frequently Asked Questions. All About Saw Palmetto and Prostate Health. Garden City Park, NY: Avery Publishing Group, 1999.
26. Keung W-M. Dietary estrogenic isoflavones are potent inhibitors of β-hydroxysteroid dehydrogenase of P. testosteronii. Biochem Biophys Res Commun 1995;215:1137-1144.
27. Matzkin H, Soloway MS. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992;21:309-314.
28. Morton MS, Chan PSF, Cheng C, Blacklock N, Matos-Ferreira A, Abranches-Monteiro L, Correia R, Lloyd S, Griffiths K. Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997;32:122-128.
29. Nickel JC. Placebo therapy of benign prostatic hyperplasia: A 25-month study. Canadian PROSPECT Study Group. Br J Urol 1998;81:383-387.
30. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault J-P, Afridi SK, Elhilali MM, and the PROSPECT Study Group. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two-year Study. CMAJ 1996;155:1251-1259.
31. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993;22:335-345.
32. Pollard M, Luckert PH. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr Cancer 1997;28:41-45.
33. Proscarr® (finasteride) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc, 2001.
34. Record IR, Dreosti IE, McInerney JK. The antioxidant activity of genistein in vitro. J Nutr Biochem 1995;6:481-485.
35. Servadio C, Braf Z, Siegel Y, Leib Z, Saranga R, Lindner A. Local thermotherapy of the benign prostate: A 1-year follow-up. Eur Urol 1990;18:169-173.
36. Setchell KDR, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131(Suppl):1362S-1375S.
37. Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992;43:557-564.
38. Stephens FO. Phytoestrogens and prostate cancer: possible preventive role. Med J Aust 1997;167:138-140.
39. Sun X-Y, Plouzek CA, Henry JP, Wang TTY, Phang JM. Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res 1998;58:2379-2384.
40. Wang TTY, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996;17:271-5.